CME articleNeoadjuvant hormonal therapy: The Canadian experience
References (45)
- et al.
Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist
Urology
(1994) Natural history of low-stage prostatic cancer and the impact of early detection
Urol Clin North Am
(1990)Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
J Urol
(1991)- et al.
Total prostatectomy for clinically localized prostate cancer: long-term results
J Urol
(1989) - et al.
Understaging and undergrading of prostate cancer: Argument for postoperative radiation as adjuvant therapy
Urology
(1983) - et al.
Staging errors in clinically localized prostatic cancer
J Urol
(1982) - et al.
Radical retropubic prostatectomy for cancer: a 20-year experience
J Urol
(1977) - et al.
Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate
J Urol
(1982) - et al.
Radical prostatectomy for carcinoma of the prostate. 1951–1976; A review of 329 patients
J Urol
(1977) - et al.
Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration
Urology
(1993)
Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended follow-up
J Urol
Endocrine therapy for prostate cancer
Endocrinol Metab Clin North Am
Cancer statistics 1996
CA Cancer J Clin
The economic burden of cancer
Temporary combination therapy with flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer
Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma
Radiology
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen
Urology
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
New Engl J Med
Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer
J Urol
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer
Cancer
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen
Clin Invest Med
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide lupron: the first controlled and randomized trial
Clin Invest Med
Cited by (88)
Androgen deprivation therapy in localized prostate cancer. Current status and future trends
2023, Actas Urologicas EspanolasApproach to the Patient with High-Risk Prostate Cancer
2017, Urologic Clinics of North AmericaCitation Excerpt :There is also renewed interest in neoadjuvant therapy before surgery using new agents that can better achieve more complete androgen blockage. Older studies of neoadjuvant ADT failed to demonstrate an overall survival advantage, but these trials were limited by incomplete androgen ablation and overrepresentation of patients with low-risk cancer who were unlikely to die from their disease (such as men with Gleason 6 disease).58–70 New studies are focusing on complete androgen blockade (using agents such as abiraterone acetate and enzalutamide) in high-risk patients who are likely to fail local therapy.71–74
Neoadjuvant before surgery treatments: State of the art in prostate cancer
2014, Progres en UrologieSurgical Management of Prostate Cancer
2013, Hematology/Oncology Clinics of North AmericaCitation Excerpt :Thus, finding TP5 has significant clinical consequences for post-RP patient management. Several studies have explored the use of neoadjuvant androgen deprivation therapy (ADT) before prostatectomy.103–110 The initial results were encouraging, with improvements in several pathologic characteristics.
Androgen deprivation and cardiovascular risk in prostate cancer treatment
2012, Progres en UrologieAndrogen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer
2012, Journal of Steroid Biochemistry and Molecular Biology